Investigator
Research Fellow · Dana-Farber Cancer Institute, radiation oncology
A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors
DNA polymerase theta (POLθ) is synthetic lethal with Homologous Recombination (HR) deficiency and thus a candidate target for HR-deficient cancers. Through high-throughput small molecule screens we identified the antibiotic Novobiocin (NVB) as a specific POLθ inhibitor that selectively kills HR-deficient tumor cells
Research Fellow
Dana-Farber Cancer Institute · radiation oncology
Researcher
Harvard Medical School
US
